# EDGAR Filing Document

**Accession Number:** 0001752828
**File Stem:** 0001493152-25-021312
**Filing Date:** 2025-11
**Character Count:** 23001
**Document Hash:** 3c7191113d21398018644a24c465424a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-021312.hdr.sgml**: 20251107

**ACCESSION NUMBER**: 0001493152-25-021312

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20251107

**DATE AS OF CHANGE**: 20251107

**EFFECTIVENESS DATE**: 20251107

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Celularity Inc
- **CENTRAL INDEX KEY:** 0001752828
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831702591
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291392
- **FILM NUMBER:** 251463526

**BUSINESS ADDRESS:**
- **STREET 1:** 170 PARK AVE
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932
- **BUSINESS PHONE:** (908) 768-2170

**MAIL ADDRESS:**
- **STREET 1:** 170 PARK AVE
- **CITY:** FLORHAM PARK
- **STATE:** NJ
- **ZIP:** 07932

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GX Acquisition Corp.
- **DATE OF NAME CHANGE:** 20180912

**As filed with the Securities and Exchange Commission on November 7, 2025**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT** 

**UNDER**

**THE SECURITIES ACT OF 1933**

**CELULARITY INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **83-1702591** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |

---

---

| | |
|:---|:---|
| **170 Park Ave** |  |
| **Florham Park, New Jersey** | **07932** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**Celularity Inc. 2021 Equity Incentive Plan** 

(Full title of the plan)

**Robert J. Hariri, M.D., Ph.D.**

**Chief Executive Officer**

**Celularity Inc.**

**170 Park Ave**

**Florham Park, New Jersey 07932**

(Name and address of agent for service)

**(908) 768-2170**

(Telephone number, including area code, of agent for service)

***Copies to:***

**Jeffrey J. Fessler, Esq.**

**Nazia J. Khan, Esq.**

**Sheppard, Mullin, Richter & Hampton LLP**

**30 Rockefeller Plaza**

**New York, NY 10112-0015**

**Tel.: (212) 653-8700**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

Celularity Inc. ("Celularity" or "Company") is filing this Registration Statement on Form S-8 to register an additional 2,270,311 shares of its Class A common stock, par value $0.0001 per share, issuable under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan").

Pursuant to the terms of the 2021 Plan, the number of shares of Class A common stock reserved for issuance thereunder is subject to automatic annual increases. Celularity did not file a Registration Statement on Form S-8 to register the shares added to the share reserves under the 2021 Plan for the 2023 and 2024 calendar years. Accordingly, this Registration Statement registers the additional shares reserved for issuance under the 2021 Plan as of January 1, 2023, January 1, 2024 and January 1, 2025. As such, this Registration Statement registers 2,270,311 additional shares of Class A common stock available for issuance under the 2021 Plan as a result of the foregoing.

The Company previously filed with the Securities and Exchange Commission registration statements on Form S-8 on October 4, 2021 (File No. 333-260025) and August 11, 2022 (Fil No. 333-266783) (the "Prior Registration Statements") registering shares of Class A common stock issuable under the 2021 Plan. This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E to Form S-8 regarding registration of additional securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except for Items 3 and 8, which are being updated by this Registration Statement.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE.**

The following documents filed by the Company with the SEC pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are incorporated herein by reference:

● The Company's Annual
 Report on Form 10-K and 10-K/A for the fiscal year ended December 31, 2024, filed with
 the SEC on [May 8, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225009319/form10-k.htm) and [May 21, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225011942/form10-ka.htm) , respectively;

● The Company's Quarterly
 Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed
 with the SEC on [August 29, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225026056/form10-q.htm) and [August 29, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225026067/form10-q.htm) , respectively;

● The Company's Current Reports on Form 8-K and
 8-K/A (excluding any reports or portions thereof that are deemed to be furnished and not filed) filed with the SEC on [January 3, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000149315225000294/form8-k.htm) , [January 24, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000149315225003635/form8-k.htm) , [January 27, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000149315225003722/form8-k.htm) , [February 18, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000149315225007097/form8-k.htm) , [February 24, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000149315225007986/form8-k.htm) , [March 21, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000149315225011156/form8-k.htm) , [April 23, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225005884/form8-k.htm) , [May 1, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225008104/form8-k.htm) , [May 16, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225011253/form8-k.htm) , [May 20, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225011751/form8-k.htm) , [June 6, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225014073/form8-k.htm) , [June 10, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225014525/form8-k.htm) , [July 22, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225020580/form8-k.htm) , [July 29, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225021378/form8-ka.htm) , [July 30, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225021556/form8-k.htm) , [August 1, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225021831/form8-k.htm) , [August 12, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225023231/form8-k.htm) , [August 18, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225024623/form8-k.htm) , [September 3, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000164117225026245/form8-k.htm) and [October 28, 2025](https://www.sec.gov/Archives/edgar/data/1752828/000149315225019839/form8-k.htm) ;

● The
 description of the Company's Class A common stock which is contained in the Company's Registration Statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1752828/000121390019009074/f8a12b051719_gxacquisition.htm) filed on May 17, 2019 (File No. 001-38914) under the Exchange Act, including any amendments
 or reports filed with the SEC for the purpose of updating such description; and

● A ll
 other reports and documents filed by the Company pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than Current
 Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) subsequent
 to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that
 indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed
 to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such reports and
 documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to
 be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any subsequently
 filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement
 so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

**PART II<br>** 

<br> **INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8. Exhibits.**

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| 4.1 | [Specimen Common Stock Certificate of the Company (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Commission on July 22, 2021).](https://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex4-1_celularity.htm) |
| 5.1\* | [Opinion of Sheppard, Mullin, Richter & Hampton LLP.](ex5-1.htm) |
| 10.1+ | [Celularity Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 to the registration statement on Form S-8 (File No. 333-260025), filed with the Commission on October 4, 2021).](https://www.sec.gov/Archives/edgar/data/1752828/000101376221000108/ea147925ex99-3_celularity.htm) |
| 10.2+ | [Forms of Stock Option Grant Notice, Option Agreement, Notice of Exercise, RSU Award Grant Notice and Award Agreement under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 99.4 to the registration statement on Form S-8 (File No. 333-260025), filed with the Commission on October 4, 2021).](https://www.sec.gov/Archives/edgar/data/1752828/000101376221000108/ea147925ex99-4_celularity.htm) |
| 23.1\* | [Consent of EisnerAmper LLP, independent registered public accounting firm.](ex23-1.htm) |
| 23.2\* | [Consent of Deloitte & Touche LLP](ex23-2.htm) |
| 23.3\* | [Consent of Sheppard, Mullin, Richter & Hampton LLP (included in Exhibit 5.1).](ex5-1.htm) |
| 24.1\* | [Power of Attorney (included on signature page of this registration statement).](#a_001) |
| 107\* | [Filing Fee Table.](ex107.htm) |

---

\* Filed herewith.

+ Indicates a management contract or any compensatory plan, contract or arrangement.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Florham Park, New Jersey, on the 7 day of November, 2025.

---

| | |
|:---|:---|
| **CELULARITY INC.** | **CELULARITY INC.** |
| By: | */s/ Robert J. Hariri* |
| Name: | Robert J. Hariri |
| Title: | Chief Executive Officer |

---

**POWER OF ATTORNEY AND SIGNATURES**

KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints each of Robert J. Hariri M.D., Ph.D. and Joseph C. DosSantos as such person's true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following person in the capacities and on the date indicated below.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Robert J. Hariri* | President and Chief Executive Officer (Principal Executive Officer) | November 7, 2025 |
| Robert J. Hariri, M.D., Ph.D. |  |  |
| */s/ Joseph C. DosSantos* | Acting Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | November 7, 2025 |
| Joseph C. DosSantos |  |  |
| */s/ Peter Diamandis* | Director | November 7, 2025 |
| Peter Diamandis, M.D. |  |  |
| */s/ Geoffrey Ling, M.D., Ph.D.* | Director | November 7, 2025 |
| Geoffrey Ling |  |  |
| */s/ Diane Parks* | Director | November 7, 2025 |
| Diane Parks |  |  |
| */s/ Vincent LeVien* | Director | November 7, 2025 |
| Vincent LeVien |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](ex5-1_001.jpg) | Sheppard, Mullin, Richter & Hampton LLP<br> 30 Rockefeller Plaza<br> New York, New York 10112-0015<br> 212.653.8700 main<br> 212.653.8701 fax<br> www.sheppardmullin.com |

---

November 7, 2025

**<u>VIA ELECTRONIC MAIL</u>**

Celularity Inc.

170 Park Ave

Florham Park, New Jersey 07932

Re: <u>Registration Statement on Form S-8</u>

Ladies and Gentlemen:

You have requested our opinion with respect to certain matters in connection with the filing by Celularity Inc., a Delaware corporation (the "Company"), of a Registration Statement on Form S-8 (the "Registration Statement") under the Securities Act of 1933, as amended (the "Securities Act"), with the U.S. Securities and Exchange Commission (the "Commission"), covering 2,270,311 shares (the "Shares") of the Company's Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), which may be issued pursuant to the Company's 2021 Equity Incentive Plan (the "Plan").

This opinion (this "Opinion") is being furnished in accordance with the requirements of Item 8 of Form S-8 and Item 601(b)(5)(i) of Regulation S-K.

In connection with this Opinion, we have reviewed and relied upon the Registration Statement, the Company's Second Amended and Restated Certificate of Incorporation, as amended, as in effect on the date hereof (the "Certificate of Incorporation"), the Company's Amended and Restated Bylaws as in effect on the date hereof (the "Bylaws" and together with the Certificate of Incorporation, the "Charter Documents"), the proceedings taken by the Company with respect to the authorization and adoption of the Plan, resolutions adopted by the board of directors of the Company, and such other documents, records, certificates, memoranda and other instruments as we deem necessary as a basis for this Opinion.

With respect to the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the conformity to the original of all documents submitted to us as certified or reproduced copies. We have also assumed that the Shares will be uncertificated in accordance with Section 158 of the Delaware General Corporation Law, and the transfer agent therefor will register the purchaser thereof as the registered owner of any uncertificated Shares on its stock transfer books and records. We have further assumed that (a) shares of Class A Common Stock currently reserved for issuance under the Plan will remain available for the issuance of the Shares, and (b) neither the Company's Charter Documents nor any of the proceedings relating to either the Plan or any of the award agreements relating to the Shares will be rescinded, amended or otherwise modified prior to the issuance of the Shares. We have also obtained from public officials and officers of the Company certificates or comparable documents as to certain factual matters and, insofar as this Opinion is based on matters of fact, we have relied on such certificates and comparable documents without independent investigation. We have made such other investigations as we have deemed relevant and necessary in connection with the opinions hereinafter set forth.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when issued and sold in the manner referred to in the Plan and against proper payment and consideration thereof and pursuant to the agreements that accompany the Plan, will be legally and validly issued, fully paid and nonassessable.

We consent to the filing of this Opinion as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

![](ex5-1_001.jpg)

We express no opinion as to matters governed by any laws other than the Delaware General Corporation Law and reported decisions of the Delaware courts interpreting such law.

This Opinion is rendered as of the date first written above, and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter may be brought to our attention and which may alter, affect or modify the opinion expressed herein. Our opinion is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any other matters relating to the Company, the Shares, the Plan, the award agreements related to the Shares, or the Registration Statement.

---

| |
|:---|
| Respectfully Submitted, |
| */s/ Sheppard, Mullin, Richter & Hampton LLP* |
| SHEPPARD, MULLIN, RICHTER & HAMPTON LLP |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement of Celularity, Inc. on Form S-8 to be filed on or about November 7, 2025 of our report dated May 8, 2025, on our audit of the financial statements as of December 31, 2024 and for the year then ended, which report was included in the Annual Report on Form 10-K filed May 8, 2025. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company's ability to continue as a going concern.

*/s/ EisnerAmper LLP*

EISNERAMPER LLP

Iselin, New Jersey

November 7, 2025

## Exhibit 23.2

**Exhibit 23.2**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statements on Form S-8 of our report dated July 30, 2024 (May 8, 2025, as to the effects of the adoption of ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, described in Note 2), relating to the financial statements of Celularity, Inc. appearing in the Annual Report on Form 10-K of Celularity Inc., for the year ended December 31, 2024.

---

| |
|:---|
| /s/ Deloitte & Touche LLP |
| Morristown, New Jersey |
| November 7, 2025 |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107** 

**Calculation of Filing Fee Tables** 

**Form S-8** 

(Form Type)

**Celularity Inc.**

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| Security<br> Type | Security Class Title | Fee<br> Calculation<br> Rule<sup>(1)</sup> | Amount<br> Registered<sup>(2)</sup> | Proposed<br> Maximum<br> Offering<br> Price<br> Per Unit | Maximum<br> Aggregate<br> Offering<br> Price | Fee Rate | Amount of<br> Registration<br> Fee |
| Equity | Class A Common Stock, $0.0001 par value | Other | 2270311<sup>(3)</sup> | $1.68<sup>(1)</sup> | $3814122 | $0.00013810 | $527 |
| &nbsp;&nbsp;&nbsp;Total Offering Amount | &nbsp;&nbsp;&nbsp;Total Offering Amount | &nbsp;&nbsp;&nbsp;Total Offering Amount |  |  | $3814122 |  | $527 |
| &nbsp;&nbsp;&nbsp;Total Fees Previously Paid | &nbsp;&nbsp;&nbsp;Total Fees Previously Paid | &nbsp;&nbsp;&nbsp;Total Fees Previously Paid |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due |  |  |  |  | $527 |

---

(1) Estimated
 solely for purposes of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended
 (the "Securities Act"), by averaging the high and low sales prices of Celularity Inc.'s (the "Registrant's")
 Class A common stock, par value $0.0001 per share ("Class A Common Stock"), as reported on The Nasdaq Capital Market
 on November 4, 2025, which date is within five business days prior to the filing of this Registration Statement.

(2) Pursuant
 to Rule 416(a) under the Securities Act, this Registration Statement shall also cover an indeterminate number of additional shares
 of Class A Common Stock of the Registrant which become issuable under the Registrant's 2021 Equity Incentive Plan (the "2021
 Plan") by reason of any stock dividend, stock split, recapitalization or other similar transaction that increases the number
 of outstanding shares of Class A Common Stock. In addition, pursuant to Rule 416(c) under the
 Securities Act, this Registration Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant
 to the employee benefit plans described herein.

(3) Represents
 an aggregate of 2,270,311 additional shares of Class A Common Stock available for issuance under the 2021 Plan that were automatically
 added to the shares authorized for issuance under the 2021 Plan on January 1, 2023, January 1, 2024 and January 1, 2025 pursuant
 to an annual "evergreen" increase provision contained in the 2021 Plan.

N/A